Back to News
Market Impact: 0.52
Novartis shares fall after second major trial setback in days
Source: The Globe and Mail
Healthcare & BiotechCompany Fundamentals
Novartis said its experimental treatment for a muscle-wasting disorder failed a late-stage clinical trial, marking its second major trial setback within days. The news drove Novartis shares down about 9%, among the Swiss drugmaker's worst trading days on record, and raises pipeline-execution concerns.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.72
Ticker Sentiment
NVS-0.95
More News
- Newamsterdam Pharma stock hits 52-week low at 19.57 USD
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More